NCT02127788View on ClinicalTrials.gov

Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology

CompletedOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

July 3, 2014

Primary Completion Date

January 27, 2016

Study Completion Date

January 27, 2016

Conditions
Antifungal ProphylaxisHaemopathy
Interventions
DRUG

Micafungin

intravenous

Trial Locations (17)

13273

Site, Marseille

13385

Site, Marseille

29609

Site, Brest

33076

Site, Bordeaux

34295

Site, Montpellier

34525

Site, Béziers

37042

Site, Limoges

44093

Site, Nantes

44933

Site, Angers

49933

Site, Angers

54511

Site, Vandœuvre-lès-Nancy

57038

Site, Metz

59037

Site, Lille

63003

Site, Clermont-Ferrand

75012

Site, Paris

75019

Site, Paris

97400

Site, Saint-Denis La Réunion

All Listed Sponsors
lead

Astellas Pharma S.A.S.

INDUSTRY

NCT02127788 - Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology | Biotech Hunter | Biotech Hunter